<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04254640</url>
  </required_header>
  <id_info>
    <org_study_id>AML-2020</org_study_id>
    <nct_id>NCT04254640</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML</brief_title>
  <official_title>Efficacy and Safety of Cladribine in Combination With G-CSF,Low-dose Cytarabine and Aclarubicin in Newly Diagnosed Unfit Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators conducted a phase II trial that evaluated the efficacy and&#xD;
      safety of cladribine in combination with modified CAG regimen (low-dose cytarabine and&#xD;
      aclarubicin) in elderly patients with AML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The low-intensity chemotherapy were developed to reduce the early mortality and improve the&#xD;
      benefit-risk ratio for longterm survival in elderly or unfit AML patients.Previous studies&#xD;
      revealed that the standard dose of CAG regimen consisting of low-dose cytarabine and&#xD;
      aclarubicin in combination with granulocyte colonystimulating factor (G-CSF) priming as an&#xD;
      induction therapy was well-tolerated by patients and led to a complete remission (CR) rate of&#xD;
      50.0% in patients aged≥ 70 years. Cladribine (2-chlorodeoxyadenosine ) is a nucleoside&#xD;
      analogue of anti-adenosine deaminase that has extensive antitumor activity in hematological&#xD;
      tumor.The purine analog 2-CdA increases the uptake of Ara-C and the accumulation of its&#xD;
      active cytotoxic metabolite 5α-triphosphate Ara-C (Ara-CTP) in leukemia cells. This finding&#xD;
      suggests that synergy occurs between cladribine and cytarabine. In this study, the&#xD;
      investigators conducted a phase II trial that evaluated the efficacy and safety of cladribine&#xD;
      in combination with modified CAG regimen (low-dose cytarabine and aclarubicin) in unfit&#xD;
      patients with AML.Patients will receive C-CAG regimen as follows: cladribine 5 mg/m2, d1-5;&#xD;
      G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per&#xD;
      cycle. The participants are permitted to quit the study if complete remission (CR) was not&#xD;
      achieved after two courses of chemotherapy.The participants will be treated for a total of&#xD;
      six cycles unless disease progression or unacceptable side effects are observed or&#xD;
      participants withdrew their consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Complete Remission (CR) / CR with incomplete blood count (CRi) rate</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Cumulative CR/CRi rate during 2 cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Cladribine in Combination With CAG determined by the type, frequency, severity and relationship of adverse events to study treatment</measure>
    <time_frame>1 years</time_frame>
    <description>Safety and tolerability of Cladribine in Combination With treatment for CAG for AML (type, frequency, severity and relationship of adverse events to study treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The time from registration to induction failure, death or relapse whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the date of registration to the date of death, whatever the cause. Patients still alive at the date last contact will be censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of MRD</measure>
    <time_frame>9 months and at relapse</time_frame>
    <description>Assessment of the prognostic value of Minimal Residual Disease (MRD) by flowcytometry or PCR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Elderly Patients</condition>
  <condition>Newly Diagnosed</condition>
  <arm_group>
    <arm_group_label>C-CAG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine Injection</intervention_name>
    <description>Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.</description>
    <arm_group_label>C-CAG</arm_group_label>
    <other_name>2-chlorodeoxyadenosine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclarubicin</intervention_name>
    <description>aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.</description>
    <arm_group_label>C-CAG</arm_group_label>
    <other_name>aclarubicin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.</description>
    <arm_group_label>C-CAG</arm_group_label>
    <other_name>Granulocyte Colony-Stimulating Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.</description>
    <arm_group_label>C-CAG</arm_group_label>
    <other_name>cytarabine hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with:&#xD;
&#xD;
          1. a diagnosis of AML according to WHO 2016 classification (excluding acute promyelocytic&#xD;
             leukemia) including secondary AML (after an antecedent hematological disease (e.g.&#xD;
             MDS) and therapy-related AML&#xD;
&#xD;
          2. Patients 60 years and older.&#xD;
&#xD;
          3. Patients NOT eligible for standard chemotherapy, defined as hematopoietic cell&#xD;
             transplantation comorbidity index (HCT-CI) ≥ 3 or Patients NOT eligible for standard&#xD;
             chemotherapy for other reasons (wish of patient).&#xD;
&#xD;
          4. White blood cell (WBC) ≤ 10 x109/L (prior hydroxyurea allowed for a maximum of 5 days,&#xD;
             stop 2 days before start cladribine treatment)&#xD;
&#xD;
          5. Adequate renal and hepatic functions unless clearly disease related as indicated by&#xD;
             the following laboratory values:&#xD;
&#xD;
               -  Serum creatinine ≤ 221.7 µmol/L (≤ 2.5 mg/dL ), unless considered AML-related&#xD;
                  -Serum bilirubin ≤ 2.5 x upper limit of normal (ULN), unless considered AML-&#xD;
&#xD;
               -  related or due to Gilbert's syndrome&#xD;
&#xD;
               -  Alanine transaminase (ALT) ≤ 2.5 x ULN, unless considered AML-related&#xD;
&#xD;
          6. WHO performance status 0, 1 or 2.&#xD;
&#xD;
          7. Patient is willing and able to use adequate contraception during and until 5 months&#xD;
             after the last protocol treatment.&#xD;
&#xD;
          8. Written informed consent.&#xD;
&#xD;
          9. Patient is capable of giving informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute promyelocytic leukemia.&#xD;
&#xD;
          2. Acute leukemia's of ambiguous lineage according to WHO 2016&#xD;
&#xD;
          3. Patient has symptomatic central nervous system (CNS) leukemia (NO routinely lumbar&#xD;
             puncture required to investigate CNS involvement)&#xD;
&#xD;
          4. Blast crisis of chronic myeloid leukemia.&#xD;
&#xD;
          5. Diagnosis of any previous or concomitant malignancy is an exclusion criterion:&#xD;
&#xD;
          6. except when the patient completed successfully treatment (chemotherapy and/or surgery&#xD;
             and/or radiotherapy) with curative intent for this malignancy at least 6 months prior&#xD;
             to randomization. OR&#xD;
&#xD;
          7. except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the&#xD;
             cervix&#xD;
&#xD;
          8. Patients previously treated for AML (any antileukemic therapy including&#xD;
             investigational agents), a short treatment period ( ≤ 5 days) with Hydroxyurea is&#xD;
             allowed&#xD;
&#xD;
          9. Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than&#xD;
             hydroxyurea&#xD;
&#xD;
         10. Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes,&#xD;
             infection, hypertension, pulmonary disease etc.)&#xD;
&#xD;
         11. Cardiac dysfunction as defined by:&#xD;
&#xD;
               -  Myocardial infarction within the last 3 months of study entry, or&#xD;
&#xD;
               -  Reduced left ventricular function with an ejection fraction &lt; 40% as measured by&#xD;
                  MUGA scan or echocardiogram or&#xD;
&#xD;
               -  Unstable angina or&#xD;
&#xD;
               -  New York Heart Association grade IV congestive heart failure or&#xD;
&#xD;
               -  Unstable cardiac arrhythmias.&#xD;
&#xD;
         12. History of stroke or intracranial hemorrhage within 6 months prior to randomization.&#xD;
&#xD;
         13. Patient has a history of human immunodeficiency virus or active infection with&#xD;
             Hepatitis C or B.&#xD;
&#xD;
         14. Patients known to be pregnant&#xD;
&#xD;
         15. Patients with a history of non-compliance to medical regimens or who are considered&#xD;
             unreliable with respect to compliance.&#xD;
&#xD;
         16. Patients with any serious concomitant medical condition which could, in the opinion of&#xD;
             the investigator, compromise participation in the study.&#xD;
&#xD;
         17. Patients who have senile dementia, mental impairment or any other psychiatric disorder&#xD;
             that prohibits the patient from understanding and giving informed consent.&#xD;
&#xD;
         18. Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wang hua, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>sun yat-sun university cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wang hua, MD.</last_name>
    <phone>0086-02087342462</phone>
    <email>wanghua@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>hua wang, MD.</last_name>
      <phone>0086-02087342462</phone>
      <email>wanghua@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>wanghua</investigator_full_name>
    <investigator_title>Director, Head of hematology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Aclarubicin</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

